Microbiota as a mediator of cancer progression and therapy
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
&NA; Complex and intricate circuitries regulate cellular proliferation, survival, and growth, and alterations of this network through genetic and epigenetic events result in aberrant cellular behaviors, often leading to carcinogenesis. Although specific germline mutations have been recognized as cancer inducers, the vast majority of neoplastic changes in humans occur through environmental exposure, lifestyle, and diet. An emerging concept in cancer biology implicates the microbiota as a powerful environmental factor modulating the carcinogenic process. For example, the intestinal microbiota influences cancer development or therapeutic responses through specific activities (immune responses, metabolites, microbial structures, and toxins). The numerous effects of microbiota on carcinogenesis, ranging from promoting, preventing, or even influencing therapeutic outcomes, highlight the complex relationship between the biota and the host. In this review, we discuss the latest findings on this complex microbial interaction with the host and highlight potential mechanisms by which the microbiota mediates such a wide impact on carcinogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893 · cited 2×
“Ipilimumab, an antibody against the immune checkpoint protein cytotoxic T-lymphocyte–associated protein 4 (CTLA-4), is used mainly to treat metastatic melanoma and often leads to colitis development in patients because of poor function of Tregs.114 Recent studies showed that intestinal reconstitution of microbiota-dep…”
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 6×
“PD-L1 blockade showed better outcomes in JAX mice than TAC, as assessed by tumor growth inhibition and antitumor CD81 T cell response.(122) Microbiota analyses revealed that Bifidobacterium was strongly associated with the antitumor T cell response.”
InfluentialAnticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 6×
“Clinically, the intestinal microbiota of patients with metastatic melanoma can be distinguished into 3 clusters: cluster A driven by the Alloprevotella or Prevotella, and clusters B and C by distinct Bacteroides spp.(115) After ipilimumab (anti–CTLA-4) therapy, many cluster B patients switch to cluster C.”
InfluentialGut microbiota, metabolites and host immunity
Rooks, M. G., & Garrett, W. S. (2016) · Nature reviews. Immunology · doi:10.1038/nri.2016.42 · Cited by 3,409
Dewhirst, F. E., Chen, T., Izard, J., Paster, B. J., Tanner, A. C. R., Yu, W.-H., Lakshmanan, A., & Wade, W. G. (2010) · Journal of Bacteriology · doi:10.1128/jb.00542-10 · Cited by 3,352
Kostic, A. D., Chun, E., Robertson, L., Glickman, J. N., Gallini, C. A., Michaud, M., Clancy, T. E., Chung, D. C., Lochhead, P., Hold, G. L., et al. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.07.007 · Cited by 2,718 · cited 2×
“nucleatum–colonized mice and RNA-sequencing data of human CRC patients suggest a positive association between the bacteria and the presence of tumorinfiltrating myeloid cells.(96) In vitro assays with primary human cells suggest that F.”
Singh, N., Gurav, A., Sivaprakasam, S., Brady, E., Padia, R., Shi, H., Thangaraju, M., Prasad, P. D., Manicassamy, S., Munn, D. H., et al. (2014) · Immunity · doi:10.1016/j.immuni.2013.12.007 · Cited by 2,368 · cited 1×
“The cytoprotective effects of butyrate have been shown to depend on the receptor Gpr109a, as genetic deletion results in a significant increase in colonic tumors.(46) Interestingly, diet intervention was able to alter the production of these microbial metabolites.”
Intestinal inflammation targets cancer-inducing activity of the microbiota
Arthur, J. C., Perez-Chanona, E., Mühlbauer, M., Tomkovich, S., Uronis, J. M., Fan, T.-J., Campbell, B. J., Abujamel, T., Dogan, B., Rogers, A. B., et al. (2012) · Science · doi:10.1126/science.1224820 · Cited by 2,263
Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
Yoshimoto, S., Loo, T. M., Atarashi, K., Kanda, H., Sato, S., Oyadomari, S., Iwakura, Y., Oshima, K., Morita, H., Hattori, M., et al. (2013) · Nature · doi:10.1038/nature12347 · Cited by 2,219
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050
Research works printed but not linked: 72
- Stratton, 2009, The cancer genome, Nature, 458, 719, 10.1038/nature07943 · DOI · Paper page
- Vogelstein, 2013, Cancer genome landscapes, Science, 339, 1546, 10.1126/science.1235122 · DOI · Paper page
- Garraway, 2013, Lessons from the cancer genome, Cell, 153, 17, 10.1016/j.cell.2013.03.002 · DOI · Paper page
- Anand, 2008, Cancer is a preventable disease that requires major lifestyle changes, Pharm Res, 25, 2097, 10.1007/s11095-008-9661-9 · DOI · Paper page
- Whiteside, 2015, The microbiome of the urinary tract–a role beyond infection, Nat Rev Urol, 12, 81, 10.1038/nrurol.2014.361 · DOI · Paper page
- Canny, 2008, Bacteria in the intestine, helpful residents or enemies from within?, Infect Immun, 76, 3360, 10.1128/IAI.00187-08 · DOI · Paper page
- Spor, 2011, Unravelling the effects of the environment and host genotype on the gut microbiome, Nat Rev Microbiol, 9, 279, 10.1038/nrmicro2540 · DOI · Paper page
- Fujimura, 2015, Microbiota in allergy and asthma and the emerging relationship with the gut microbiome, Cell Host Microbe, 17, 592, 10.1016/j.chom.2015.04.007 · DOI · Paper page
- Scher, 2011, The microbiome and rheumatoid arthritis, Nat Rev Rheumatol, 7, 569, 10.1038/nrrheum.2011.121 · DOI · Paper page
- Ussar, 2015, Interactions between gut microbiota, host genetics and diet modulate the predisposition to obesity and metabolic syndrome, Cell Metab, 22, 516, 10.1016/j.cmet.2015.07.007 · DOI · Paper page
- Borges-Canha, 2015, Role of colonic microbiota in colorectal carcinogenesis: a systematic review, Rev Esp Enferm Dig, 107, 659, 10.17235/reed.2015.3830/2015 · DOI · Paper page
- De Martel, 2012, Global burden of cancers attributable to infections in 2008: a review and synthetic analysis, Lancet Oncol, 13, 607, 10.1016/S1470-2045(12)70137-7 · DOI · Paper page
- Jobin, 2013, Colorectal cancer: looking for answers in the microbiota, Cancer Discov, 3, 384, 10.1158/2159-8290.CD-13-0042 · DOI
- Gao, 2015, Microbiota disbiosis is associated with colorectal cancer, Front Microbiol, 6, 20, 10.3389/fmicb.2015.00020 · DOI · Paper page
- Narayanan, 2014, Human fecal microbiome-based biomarkers for colorectal cancer, Cancer Prev Res (Phila), 7, 1108, 10.1158/1940-6207.CAPR-14-0273 · DOI
- Pevsner-Fischer, 2016, Role of the microbiome in non-gastrointestinal cancers, World J Clin Oncol, 7, 200, 10.5306/wjco.v7.i2.200 · DOI
- Riley, 2013, Bacteria-human somatic cell lateral gene transfer is enriched in cancer samples, PLoS Comput Biol, 9, e1003107, 10.1371/journal.pcbi.1003107 · DOI · Paper page
- Yamamoto, 2013, Intestinal bacteria modify lymphoma incidence and latency by affecting systemic inflammatory state, oxidative stress, and leukocyte genotoxicity, Cancer Res, 73, 4222, 10.1158/0008-5472.CAN-13-0022 · DOI
- Witkowska, 2013, Helicobacter pylori infection, chronic inflammation, and genomic transformations in gastric MALT lymphoma, Mediators Inflamm, 2013, 523170, 10.1155/2013/523170 · DOI
- Wotherspoon, 1993, Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori, Lancet, 342, 575, 10.1016/0140-6736(93)91409-F · DOI · Paper page
- Park, 2010, Treatment outcome of localized Helicobacter pylori-negative low-grade gastric MALT lymphoma, World J Gastroenterol, 16, 2158, 10.3748/wjg.v16.i17.2158 · DOI
- Zackular, 2013, The gut microbiome modulates colon tumorigenesis, MBio, 4, e00692, 10.1128/mBio.00692-13 · DOI · Paper page
- Son, 2015, Altered interactions between the gut microbiome and colonic mucosa precede polyposis in APCMin/+ mice, PLoS One, 10, e0127985, 10.1371/journal.pone.0127985 · DOI
- Zhan, 2013, Gut microbiota protects against gastrointestinal tumorigenesis caused by epithelial injury, Cancer Res, 73, 7199, 10.1158/0008-5472.CAN-13-0827 · DOI
- Dejea, 2014, Microbiota organization is a distinct feature of proximal colorectal cancers, Proc Natl Acad Sci U S A, 111, 18321, 10.1073/pnas.1406199111 · DOI · Paper page
- Johnson, 2015, Metabolism links bacterial biofilms and colon carcinogenesis, Cell Metab, 21, 891, 10.1016/j.cmet.2015.04.011 · DOI · Paper page
- Sesink, 1999, Red meat and colon cancer: the cytotoxic and hyperproliferative effects of dietary heme, Cancer Res, 59, 5704
- Ijssennagger, 2015, Gut microbiota facilitates dietary heme-induced epithelial hyperproliferation by opening the mucus barrier in colon, Proc Natl Acad Sci U S A, 112, 10038, 10.1073/pnas.1507645112 · DOI · Paper page
- Louis, 2014, The gut microbiota, bacterial metabolites and colorectal cancer, Nat Rev Microbiol, 12, 661, 10.1038/nrmicro3344 · DOI · Paper page
- Matanoski, 2006, Demographics and tumor characteristics of colorectal cancers in the United States, 1998-2001, Cancer, 107, 1112, 10.1002/cncr.22008 · DOI
- Cao, 2014, The secondary bile acid, deoxycholate accelerates intestinal adenoma-adenocarcinoma sequence in Apc (min/+) mice through enhancing Wnt signaling, Fam Cancer, 13, 563, 10.1007/s10689-014-9742-3 · DOI
- Donohoe, 2014, A gnotobiotic mouse model demonstrates that dietary fiber protects against colorectal tumorigenesis in a microbiota- and butyrate-dependent manner, Cancer Discov, 4, 1387, 10.1158/2159-8290.CD-14-0501 · DOI · Paper page
- Nicholson, 2012, Host-gut microbiota metabolic interactions, Science, 336, 1262, 10.1126/science.1223813 · DOI · Paper page
- Bindels, 2015, Non digestible oligosaccharides modulate the gut microbiota to control the development of leukemia and associated cachexia in mice, PLoS One, 10, e0131009, 10.1371/journal.pone.0131009 · DOI
- Kipanyula, 2013, Signaling pathways bridging microbial-triggered inflammation and cancer, Cell Signal, 25, 403, 10.1016/j.cellsig.2012.10.014 · DOI
- Davis, 2014, Emerging significance of NLRs in inflammatory bowel disease, Inflamm Bowel Dis, 20, 2412, 10.1097/MIB.0000000000000151 · DOI
- Vipperla, 2016, Diet, microbiota, and dysbiosis: a “recipe” for colorectal cancer, Food Funct, 7, 1731, 10.1039/C5FO01276G · DOI
- Cao, 2015, Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease, Nat Rev Immunol, 16, 35, 10.1038/nri.2015.8 · DOI · Paper page
- Van Der Kraak, 2015, Colitis-associated colon cancer: is it in your genes?, World J Gastroenterol, 21, 11688, 10.3748/wjg.v21.i41.11688 · DOI
- Liu, 2014, NOD2 polymorphisms associated with cancer risk: a meta-analysis, PLoS One, 9, e89340, 10.1371/journal.pone.0089340 · DOI
- Liu, 2015, Expression profile of innate immune receptors, NLRs and AIM2, in human colorectal cancer: correlation with cancer stages and inflammasome components, Oncotarget, 6, 33456, 10.18632/oncotarget.5587 · DOI
- Pédron, 2012, A crypt-specific core microbiota resides in the mouse colon, MBio, 3, 10.1128/mBio.00116-12 · DOI · Paper page
- Couturier-Maillard, 2013, NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer, J Clin Invest, 123, 700
- Alnabhani, 2016, Respective roles of hematopoietic and nonhematopoietic Nod2 on the gut microbiota and mucosal homeostasis, Inflamm Bowel Dis, 22, 763, 10.1097/MIB.0000000000000749 · DOI
- Robertson, 2013, Nod1 and Nod2 signaling does not alter the composition of intestinal bacterial communities at homeostasis, Gut Microbes, 4, 222, 10.4161/gmic.24373 · DOI · Paper page
- Ayres, 2013, Inflammasome-microbiota interplay in host physiologies, Cell Host Microbe, 14, 491, 10.1016/j.chom.2013.10.013 · DOI
- Hu, 2013, Microbiota-induced activation of epithelial IL-6 signaling links inflammasome-driven inflammation with transmissible cancer, Proc Natl Acad Sci U S A, 110, 9862, 10.1073/pnas.1307575110 · DOI · Paper page
- Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
- Man, 2015, The transcription factor IRF1 and guanylate-binding proteins target activation of the AIM2 inflammasome by Francisella infection, Nat Immunol, 16, 467, 10.1038/ni.3118 · DOI · Paper page
- Meunier, 2015, Guanylate-binding proteins promote activation of the AIM2 inflammasome during infection with Francisella novicida, Nat Immunol, 16, 476, 10.1038/ni.3119 · DOI · Paper page
- Man, 2015, Critical Role for the DNA Sensor AIM2 in Stem Cell Proliferation and Cancer, Cell, 162, 45, 10.1016/j.cell.2015.06.001 · DOI · Paper page
- Wilson, 2015, Inflammasome-independent role of AIM2 in suppressing colon tumorigenesis via DNA-PK and Akt, Nat Med, 21, 906, 10.1038/nm.3908 · DOI · Paper page
- West, 2015, Emerging cytokine networks in colorectal cancer, Nat Rev Immunol, 15, 615, 10.1038/nri3896 · DOI · Paper page
- Song, 2014, Alterations in the microbiota drive interleukin-17C production from intestinal epithelial cells to promote tumorigenesis, Immunity, 40, 140, 10.1016/j.immuni.2013.11.018 · DOI · Paper page
- Sundström, 2015, Human mucosa-associated invariant T cells accumulate in colon adenocarcinomas but produce reduced amounts of IFN-γ, J Immunol, 195, 3472, 10.4049/jimmunol.1500258 · DOI
- Ling, 2016, Circulating and tumor-infiltrating mucosal associated invariant T (MAIT) cells in colorectal cancer patients, Sci Rep, 6, 20358, 10.1038/srep20358 · DOI · Paper page
- Lévy, 2015, Intestinal inhibition of Atg7 prevents tumour initiation through a microbiome-influenced immune response and suppresses tumour growth, Nat Cell Biol, 17, 1062, 10.1038/ncb3206 · DOI · Paper page
- Geis, 2015, Regulatory T-cell response to enterotoxigenic Bacteroides fragilis colonization triggers IL17-dependent colon carcinogenesis, Cancer Discov, 5, 1098, 10.1158/2159-8290.CD-15-0447 · DOI · Paper page
- DeStefano Shields, 2016, Reduction of murine colon tumorigenesis driven by enterotoxigenic Bacteroides fragilis using cefoxitin treatment, J Infect Dis, 214, 122, 10.1093/infdis/jiw069 · DOI
- Cuevas-Ramos, 2010, Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells, Proc Natl Acad Sci U S A, 107, 11537, 10.1073/pnas.1001261107 · DOI · Paper page
- Mousa, 2016, MATE transport of the E. coli-derived genotoxin colibactin, Nature Microbiology, 1, 15009, 10.1038/nmicrobiol.2015.9 · DOI
- Yang, 2014, Microbial imbalance and intestinal pathologies: connections and contributions, Dis Model Mech, 7, 1131, 10.1242/dmm.016428 · DOI · Paper page
- Mima, 2015, Fusobacterium nucleatum and T Cells in Colorectal Carcinoma, JAMA Oncol, 1, 653, 10.1001/jamaoncol.2015.1377 · DOI · Paper page
- Belcheva, 2015, Gut microbial metabolism and colon cancer: can manipulations of the microbiota be useful in the management of gastrointestinal health?, Bioessays, 37, 403, 10.1002/bies.201400204 · DOI
- Ambalam, 2016, Probiotics, prebiotics and colorectal cancer prevention, Best Pract Res Clin Gastroenterol, 30, 119, 10.1016/j.bpg.2016.02.009 · DOI · Paper page
- Mori, 2003, Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer, Cancer Chemother Pharmacol, 51, 403, 10.1007/s00280-003-0585-0 · DOI
- Fittkau, 2004, Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats, J Cancer Res Clin Oncol, 130, 388, 10.1007/s00432-004-0557-8 · DOI
- Lin, 2014, The role of intestinal microbiota in development of irinotecan toxicity and in toxicity reduction through dietary fibres in rats, PLoS One, 9, e83644, 10.1371/journal.pone.0083644 · DOI
- Paci, 2014, Review of therapeutic drug monitoring of anticancer drugs part 1–cytotoxics, Eur J Cancer, 50, 2010, 10.1016/j.ejca.2014.04.014 · DOI · Paper page
- Frank, 2015, TLR signaling modulates side effects of anticancer therapy in the small intestine, J Immunol, 194, 1983, 10.4049/jimmunol.1402481 · DOI · Paper page
- Sistigu, 2011, Immunomodulatory effects of cyclophosphamide and implementations for vaccine design, Semin Immunopathol, 33, 369, 10.1007/s00281-011-0245-0 · DOI · Paper page
- Iida, 2013, Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment, Science, 342, 967, 10.1126/science.1240527 · DOI · Paper page
Cited by
The human tumor microbiome is composed of tumor type–specific intracellular bacteria
Nejman, D., Livyatan, I., Fuks, G., Gavert, N., Zwang, Y., Geller, L. T., Rotter-Maskowitz, A., Weiser, R., Mallel, G., Gigi, E., et al. (2020) · Science · doi:10.1126/science.aay9189 · Cited by 2,464
Gut microbiota: A player in aging and a target for anti-aging intervention
Vaiserman, A. M., Koliada, A. K., & Marotta, F. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.01.001 · Cited by 465
Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies
Panebianco, C., Andriulli, A., & Pazienza, V. (2018) · Microbiome · doi:10.1186/s40168-018-0483-7 · Cited by 298
Abraham, D., Feher, J., Scuderi, G. L., Szabo, D., Dobolyi, A., Cservenak, M., Juhasz, J., Ligeti, B., Pongor, S., Gomez-Cabrera, M. C., et al. (2019) · Experimental Gerontology · doi:10.1016/j.exger.2018.12.005 · Cited by 260
Locoregional Effects of Microbiota in a Preclinical Model of Colon Carcinogenesis
Tomkovich, S., Yang, Y., Winglee, K., Gauthier, J., Mühlbauer, M., Sun, X., Mohamadzadeh, M., Liu, X., Martin, P., Wang, G. P., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3472 · Cited by 252
Self-citationInflammasomes and Cancer: The Dynamic Role of the Inflammasome in Tumor Development
Kantono, M., & Guo, B. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01132 · Cited by 133
C-type lectin receptor-mediated immune recognition and response of the microbiota in the gut
Li, T.-H., Liu, L., Hou, Y.-Y., Shen, S.-N., & Wang, T.-T. (2019) · Gastroenterology Report · doi:10.1093/gastro/goz028 · Cited by 58
Metadata
- Authors
- Pope, J. L., Tomkovich, S., Yang, Y., & Jobin, C.
- Venue
- Translational Research
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 179
- Pages
- 139-154
- ISSN
- 1878-1810 (ISSN-L)
- 1931-5244
- OpenAlex
- W2479524302
- Cited by
- 79
- References
- 49
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Funders
- National Institutes of Health (RO1DK073338, RO1 AT08623)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.